Syros Pharmaceuticals

YTD

ALL

Why Robinhood?

You can watch SYRS and buy or sell other stocks, ETFs, and their options commission-free!

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609.

CEO

Nancy A. Simonian

CEONancy A. Simonian

Employees

124

Employees124

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2011

Founded2011

Employees

124

Employees124

SYRS Key Statistics

Market cap

1.95M

Market cap1.95M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

5.31M

Average volume5.31M

High today

$0.031

High today$0.031

Low today

$0.029

Low today$0.029

Open price

$0.029

Open price$0.029

Volume

58.57K

Volume58.57K

52 Week high

$5.22

52 Week high$5.22

52 Week low

$0.029

52 Week low$0.029

People also own

Based on the portfolios of people who own SYRS. This list is generated using Robinhood data, and it’s not a recommendation.

Syros Pharmaceuticals

Why Robinhood?

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. Show more

SYRS Key Statistics

People also own

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609.